ChiCTR2500112281 版本V1.0 版本创建时间2025/11/12 10:58:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500112281 

最近更新日期:

Date of Last Refreshed on:

2025-11-12 10:58:33 

注册时间:

Date of Registration:

2025-11-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

改良结肠拖出式延期肛管吻合术(mP-T)治疗难治性直肠肛周克罗恩病的有效性、安全性非随机对照研究

Public title:

The efficacy and safety of modified colon pull-out delayed anal anastomosis (mP-T) in the treatment of refractory perirectal Crohn's disease were non-randomized controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

改良结肠拖出式延期肛管吻合术(mP-T)治疗难治性直肠肛周克罗恩病的有效性、安全性非随机对照研究

Scientific title:

The efficacy and safety of modified colon pull-out delayed anal anastomosis (mP-T) in the treatment of refractory perirectal Crohn's disease were non-randomized controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

屠倩文 

研究负责人:

丁召 

Applicant:

Qianwen Tu 

Study leader:

Zhao Ding 

申请注册联系人电话:

Applicant telephone:

+86 183 3665 7214

研究负责人电话:

Study leader's
telephone:

+86 180 6263 8859

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tuqianwen@whu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

dingzhao@whu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国湖北省武汉市武昌区水果湖街道东湖路169号

研究负责人通讯地址:

中国湖北省武汉市武昌区水果湖街道东湖路169号

Applicant address:

No. 169, Donghu Road, Fuyu Lake Street, Wuchang District, Wuhan, Hubei, China

Study leader's address:

No. 169, Donghu Road, Fuyu Lake Street, Wuchang District, Wuhan, Hubei, China

申请注册联系人邮政编码:

Applicant postcode:

430000

研究负责人邮政编码:

Study leader's postcode:

430000

申请人所在单位:

武汉大学第二临床医学院

Applicant's institution:

The Second Clinical College of Wuhan University

研究负责人所在单位:

武汉大学中南医院

Affiliation of the Leader:

Central South Hospital of Wuhan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研伦[2025300]

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

武汉大学中南医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee Zhongnan Hospital of Wuhan University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-23 00:00:00

伦理委员会联系人:

张元珍

Contact Name of the ethic committee:

Yuanzhen Zhang

伦理委员会联系地址:

中国湖北省武汉市武昌区水果湖街道东湖路169号

Contact Address of the ethic committee:

No. 169, Donghu Road, Fuyu Lake Street, Wuchang District, Wuhan, Hubei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 6781 2787

伦理委员会联系人邮箱:

Contact email of the ethic committee:

znyyll@126.com

研究实施负责(组长)单位:

武汉大学中南医院

Primary sponsor:

Central South Hospital of Wuhan University

研究实施负责(组长)单位地址:

中国湖北省武汉市武昌区水果湖街道东湖路169号

Primary sponsor's address:

No. 169, Donghu Road, Fuyu Lake Street, Wuchang District, Wuhan, Hubei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

武汉大学中南医院

具体地址:

中国湖北省武汉市武昌区水果湖街道东湖路169号

Institution
hospital:

Central South Hospital of Wuhan University

Address:

No. 169, Donghu Road, Fuyu Lake Street, Wuchang District, Wuhan, Hubei, China

经费或物资来源:

吴阶平医学基金会临床科研专项资助基金

Source(s) of funding:

Wu Jieping Medical Foundation, clinical research fund

研究疾病:

克罗恩病  

Target disease:

Crohn's disease

研究疾病代码:

DD70

Target disease code:

DD70

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

1. 主要目的:与同期未接受 mP-T 治疗的难治性直肠肛管 CD 患者相比较,观察接受 mP-T 治疗复 CD 患者术后1年的生活质量、肛门功能和疾病状态。 2. 次要目的:接受 mP-T 治疗的 RpCD 患者围手术期并发症。  

Objectives of Study:

1.Primary Objective: To compare the quality of life, anal function, and disease activity at 1 year postoperatively between patients with refractory anorectal Crohn's disease who underwent the mP-T procedure and those who did not receive this surgery during the same period. 2.Secondary Objective: To assess the incidence of perioperative complications in patients with refractory anorectal Crohn's disease undergoing the mP-T procedure.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

受试者必须满足下列所有条件方可进入试验 (1)经会阴手术复发的多发直肠会阴瘘; (2)直肠会阴瘘合并直肠阴道瘘; (3)长节段直肠纤维化严重狭窄; (4)病变累及直肠但内科治疗不佳等; (5)术前磁共振或超声影像证实括约肌环完整; (6)年龄 18-65 岁; (7)患者同意参加研究并签署知情同意书。

Inclusion criteria

Subjects must meet all of the following criteria to be enrolled in the trial: (1) Recurrent complex anorectal fistula involving the perineum; (2) Concurrent anorectal and rectovaginal fistulas; (3) Severe, long-segment rectal fibrotic stenosis; (4) Refractory rectal involvement with inadequate response to medical therapy; (5) Preoperative magnetic resonance imaging (MRI) or endoanal ultrasound confirming an intact sphincter complex; (6) Aged between 18 and 65 years; (7) Provision of written informed consent.

排除标准:

受试者必须排除下列所有条件方可进入试验: (1)急诊手术; (2)术前评估肛门功能欠佳者; (3)已参加其他临床研究; (4)合并多脏器功能不全。

Exclusion criteria:

Subjects will be excluded from the trial if they meet any of the following criteria: (1) Requiring emergency surgery; (2) Impaired anal function as assessed preoperatively; (3) Current participation in another clinical trial; (4)Concurrent multiple organ dysfunction.

研究实施时间:

Study execute time:

From 2025-11-01 00:00:00 To 2027-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-01 00:00:00 To 2027-11-30 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

30

Group:

Experimental Group

Sample size:

干预措施:

即 mP-T 组,接受 mP-T 手术治疗;

干预措施代码:

Intervention:

The mP-T group, which will undergo the modified pull-through delayed coloanal anastomosis (mP-T) procedure.

Intervention code:

组别:

对照组

样本量:

30

Group:

Control Group

Sample size:

干预措施:

对照组:接受常规内科调整药物+局部经会阴手术治疗包括并不限于挂线引流、瘘管切开、推移皮瓣修补等治疗

干预措施代码:

Intervention:

Control Group: This group will receive conventional medical therapy (drug regimen adjustment) combined with local perineal surgeries, including but not limited to seton drainage, fistulotomy, and advancement flap repair.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

武汉大学中南医院 

单位级别:

三甲 

Institution
hospital:

Central South Hospital of Wuhan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

浦东新区 

Country:

China

Province:

Shanghai

City:

Pudong New Area

单位(医院):

上海交通大学医学院附属仁济医院 

单位级别:

三甲 

Institution
hospital:

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

黄浦区 

Country:

China

Province:

Shanghai

City:

Huangpu District

单位(医院):

上海交通大学医学院附属瑞金医院 

单位级别:

三甲 

Institution
hospital:

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第六医院 

单位级别:

三甲 

Institution
hospital:

The Sixth Affiliated Hospital of Sun Yat-sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

GIQLI问卷评分

指标类型:

主要指标

Outcome:

GIQLI Questionnaire Score

Type:

Primary indicator

测量时间点:

术后半年及术后一年

测量方法:

随访

Measure time point of outcome:

At 6 months and 1 year postoperatively

Measure method:

Follow-up

指标中文名:

肠镜

指标类型:

次要指标

Outcome:

Colonoscopy

Type:

Secondary indicator

测量时间点:

术后半年及术后一年

测量方法:

肠镜检查

Measure time point of outcome:

At 6 months and 1 year postoperatively

Measure method:

Performing a colonoscopy

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/login.aspx,在试验结束6个月内上传试验数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/login.aspx, data were uploaded within 6 months after the end of the trial.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表,电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,CRF and Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-11-12 10:58:33